Evidence map›Paper›PMID 29110360›Full record

ArticleCell proliferation2018

Enhancing engineered vascular networks in vitro and in vivo: The effects of IGF1 on vascular development and durability.

Claudia C Friedrich, Yunfeng Lin, Alexander Krannich, Yinan Wu, Joseph P Vacanti, Craig M Neville

Open access · bronzeAbstract read
In one paragraph

Article in Cell proliferation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Bioengineering vascularization.Development (Cambridge, England) · 2024
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Claudia C FriedrichCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3241-6556
Yunfeng LinCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1224-6561
Alexander KrannichDepartment of Biostatistics, Clinical Research Unit, Charité Universitätsmedizin Berlin, Berlin, Germany.
Yinan WuDepartment of Biostatistics, Clinical Research Unit, Charité Universitätsmedizin Berlin, Berlin, Germany.
Joseph P VacantiCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.
Craig M NevilleCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.
Charité - Universitätsmedizin Berlin · DEHarvard University · USMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCreation of functional, durable vasculature remains an important goal within the field of regenerative medicine. Engineered biological vasculature has the potential to restore or improve human tissue function. We hypothesized that the pleotropic effects of insulin-like growth factor 1 (IGF1) would enhance the engineering of capillary-like vasculature. MATERIALS AND

methodsThe impact of IGF1 upon vasculogenesis was examined in in vitro cultures for a period of up to 40 days and as subcutaneous implants within immunodeficient mice. Co-cultures of human umbilical vein endothelial cells and human bone marrow-derived mesenchymal stem cells in collagen-fibronectin hydrogels were supplemented with either recombinant IGF1 protein or genetically engineered cells to provide sustained IGF1. Morphometric analysis was performed on the vascular networks that formed in four concentrations of IGF1.

resultsIGF1 supplementation significantly enhanced de novo vasculogenesis both in vitro and in vivo. Effects were long-term as they lasted the duration of the study period, and included network density, vessel length, and diameter. Bifurcation density was not affected. However, the highest concentrations of IGF1 tested were either ineffective or even deleterious. Sustained IGF1 delivery was required in vivo as the inclusion of recombinant IGF1 protein had minimal impact.

conclusionIGF1 supplementation can be used to produce neovasculature with significantly enhanced network density and durability. Its use is a promising methodology for engineering de novo vasculature to support regeneration of functional tissue.

Indexed as

AnimalsCells, CulturedCoculture TechniquesCollagenFibronectinsHumansHuman Umbilical Vein Endothelial CellsInsulin-Like Growth Factor IMesenchymal Stem CellsMiceModels, AnimalNeovascularization, PhysiologicTissue EngineeringCollagenFibronectinsIGF1 protein, humanInsulin-Like Growth Factor I

Identifiers

PMID29110360
PMCPMC6528972
OpenAlexW2767431203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.